August 2020

Valent and colleagues discuss the risk and impact of the recent COVID-19 pandemic in patients with mastocytosis and MCAS. The article presents expert opinion, and suggests that though the overall risk to acquire severe acute respiratory syndrome coronavirus 2 may not be elevated in these conditions, there is a greater risk of patients with mast cell disorders to develop severe COVID-19 symptoms. The work concludes that treatment of MCAS and other mast cell disorders should be evaluated on a case-by-case basis during a COVID-19 infection. This is particularly important in the case of immunosuppressive drugs.

April 2020

Lisa Kimas of the organisation Mast Attack, provides a two-part discussion and advice to patients with mast cell disorders relating to the recent COVID-19 outbreak around the world.

Become a friend

Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives. 

Become a friend


Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference to those affected by MCAS.

Make a donation